$INKT
MiNK Therapeutics, Inc. Common Stock
XNAS•Health Care•Biological Products, (No Diagnostic Substances)
MiNK Therapeutics, Inc. Common Stock
XNAS•Health Care•Biological Products, (No Diagnostic Substances)
Why is INKT down today? It is at $8.02 (-6.85%), and our scanner flagged it 6 times on unusual volume this month. See the catalyst behind the move, real-time alerts the moment INKT spikes, and full due diligence on INKT — key stats, earnings, dilution and insider activity. Free.
Our scanner flagged $INKT 6 times in the last 30 days. Create a free account to track $INKT, build a watchlist, and get instant unusual-volume alerts, with a full day of premium now and 5 more when you verify your email, no card needed.
No card · 5 premium days · join 800+ traders
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
The market is closed. Here is how INKT traded in the last session, Friday (last price and move above). Our scanner fired 2 unusual-volume and momentum alerts on INKT on Friday, peaking at 18.4x its normal volume.
Likely catalystMiNK Therapeutics, Inc.: Q3 FY2026 results, three months to Sep 30, 2026, from the latest SEC filing. Read it →Sources: float & market cap via Polygon · short interest via FINRA · borrow & shortability via Alpaca · SSR from Reg SHO 201 · filings & dilution via SEC EDGAR · analysts via Nasdaq.
Auto-generated from public data for research and education. Not investment advice.
| Insider | Action | Shares | % of position | Owns after | Value | Date |
|---|---|---|---|---|---|---|
Buell Jennifer Officer | Sold (automatic/other) | -7K 0.1% of company | sold 8.6% | 74K | $73K at $10.56 | Oct 12, 26 |
Buell Jennifer Officer | Other | 23K 0.5% of company | added 40% | 81K | n/a | Oct 11, 26 |
Corvese Brian Director | Acquired (grant/award) | +2K 0.03% of company | added 3.1% | 55K | $18K at $10.95 | Sep 1, 26 |
Ryan Barbara Director | Acquired (grant/award) | +2K 0.03% of company | added 7.4% | 24K | $18K at $10.95 | Sep 1, 26 |
Behner Peter Director | Acquired (grant/award) | +1K 0.03% of company | added 6.5% | 24K | $16K at $10.95 | Sep 1, 26 |
Holcomb John Bradley Director | Acquired (grant/award) | +1K 0.02% of company | added 36% | 5K | $14K at $10.95 | Sep 1, 26 |
Wiinberg Ulf Director | Acquired (grant/award) | +1K 0.02% of company | added 5.6% | 24K | $14K at $10.95 | Sep 1, 26 |
Ryan Barbara Director | Sold (automatic/other) | -2K 0.03% of company | sold 6.4% | 22K | $19K at $12.68 | Jun 4, 26 |
Wiinberg Ulf Director | Acquired (grant/award) | +1K 0.02% of company | added 5.3% | 23K | $14K at $12.38 | Jun 1, 26 |
Behner Peter Director | Acquired (grant/award) | +1K 0.03% of company | added 6.1% | 23K | $16K at $12.38 | Jun 1, 26 |
Corvese Brian Director | Acquired (grant/award) | +1K 0.03% of company | added 2.8% | 53K | $18K at $12.38 | Jun 1, 26 |
Ryan Barbara Director | Acquired (grant/award) | +1K 0.03% of company | added 6.5% | 23K | $18K at $12.38 | Jun 1, 26 |
Recent Form-4 filings via Nasdaq. Open-market buys are the signal worth watching. Grants and automatic (10b5-1) sells are routine. “% of position” is the share of that insider’s own holding the trade moved. Not investment advice.
Blend of news sentiment, today’s move, and community votes. Not investment advice.
News, unusual-volume alerts, AI-trader trades and community chatter - the whole story, newest first.

The tickers our scanner is lighting up most over the last 48 hours.
Comparable names in biological products, (no diagnostic substances), closest in size first.
The market is closed. Here is how INKT traded in the last session, Friday (last price and move above). Our scanner fired 2 unusual-volume and momentum alerts on INKT on Friday, peaking at 18.4x its normal volume.
INKT last traded at $8.02, down 6.85% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
The INKT Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged INKT 6 times in the last 30 days.
INKT (MiNK Therapeutics, Inc. Common Stock) trades on XNAS, with a market cap of about $41M in the Biological Products, (No Diagnostic Substances) sector.
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge INKT for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.
$INKT discussion
Sign in to ask a question or join the discussion.